secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001564590-22-019849
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio Q1 net loss $25.8M; on track to dose first SCD patient in H2 2022
------------------------------------------------------------------------------

- Net loss $25.8M ($0.48 per share); R&D spend $18.2M, G&A $7.7M.
- Cash, equivalents and investments $352.1M as of March 31, 2022; runway into Q4 2024.
- GPH101 for sickle cell disease received FDA Fast Track Designation; first patient dosing target H2 2022, proof-of-concept data in 2023.
- GPH102 for beta-thalassemia preclinical data presented at ASGCT; IND submission expected by mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000156459022019849/0001564590-22-019849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000156459022019849/grph-8k_20220512.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-019849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer